Increased Levels of Conjugated Bile Acids Are Associated with Human
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Systemic Gut Microbial Modulation of Bile Acid Metabolism in Host Tissue Compartments
Systemic gut microbial modulation of bile acid metabolism in host tissue compartments Jonathan R. Swanna,b, Elizabeth J. Wanta, Florian M. Geiera, Konstantina Spagoua, Ian D. Wilsonc, James E. Sidawayd, Jeremy K. Nicholsona,1, and Elaine Holmesa,1 aBiomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London SW7 2AZ, United Kingdom; bDepartment of Food and Nutritional Sciences, School of Chemistry, Food and Pharmacy, The University of Reading, Reading RG6 6AP, United Kingdom; cAstraZeneca, Department of Clinical Pharmacology, Drug Metabolism and Pharmacokinetics; and dAstraZeneca, Global Safety Assessment, Cheshire SK10 4TG, United Kingdom Edited by Todd R. Klaenhammer, North Carolina State University, Raleigh, NC, and approved July 30, 2010 (received for review May 26, 2010) We elucidate the detailed effects of gut microbial depletion on the deconjugation, dehydrogenation, dehydroxylation, and sulfation bile acid sub-metabolome of multiple body compartments (liver, reactions (8) to produce secondary bile acids, which are reabsorbed kidney, heart, and blood plasma) in rats. We use a targeted ultra- and returned to the liver for further processing. performance liquid chromatography with time of flight mass-spec- Historically, bile acids have been primarily viewed as detergent trometry assay to characterize the differential primary and secondary molecules important for the absorption of dietary fats and lipid- bile acid profiles in each tissue and show a major increase in the soluble vitamins in the small intestine and the maintenance of proportion of taurine-conjugated bile acids in germ-free (GF) and cholesterol homeostasis in the liver. However, their role in the antibiotic (streptomycin/penicillin)-treated rats. Although conjugated mammalian system is much broader than this, and they are now bile acids dominate the hepatic profile (97.0 ± 1.5%) of conventional recognized as important signaling molecules with systemic endo- animals, unconjugated bile acids comprise the largest proportion of crine functions. -
Bile Acid-Gut Microbiome Axis
Bile Acid-Gut Microbiome Axis The microbiome plays a major role in the biotransformation of nutrients and xenobiotics in the body, which can alter the pharmacology and/or toxicology of these chemicals. A clear example of this is how intestinal microbiota transform bile acids, which act as modulators at bile acid receptors (FXR and TGR5) to affect signaling pathways related to bile acid synthesis and energy metabolism regulation. Cayman offers a wide range of primary and secondary bile acids as well as cell-based assays for easy assessment of potential modulators of FXR and TGR5. Fat Muscle Liver TGR5 TGR5 1° Bile Acid ynthesis Stomach Large Intestine TGR5 Bile acids FXR Primary TGR5 L cells bile acids GP-1 Common Secondary bile duct bile acids Small Intestine Bile acids 2° Bile Acid ynthesis Portal vein Duodenum FXR Ileocytes FXR FXR FGF151 Bile Acids, Conjugates, and Metabolites Item No. Product Name Item No. Product Name 10011286 Chenodeoxycholic Acid* 20293 Hyocholic Acid 20250 Cholic Acid* 20294 Hyodeoxycholic Acid 9002532 Cholic Acid 7-sulfate 20253 Lithocholic Acid* 20756 Deoxycholic Acid* 20676 Lithocholic Acid 3-sulfate (sodium salt) 16942 Glycochenodeoxycholic Acid (sodium salt hydrate)* 20291 α-Muricholic Acid 20276 Glycocholic Acid* 20288 Tauro-α-muricholic Acid (sodium salt) 20274 Glycodeoxycholic Acid (hydrate) 20287 β-Muricholic Acid 22670 Glycohyocholic Acid 9003230 Glycine-β-muricholic Acid 22643 Glycohyodeoxycholic Acid 20289 Tauro-β-muricholic Acid (sodium salt) 21723 Glycolithocholic Acid 20292 ω-Muricholic Acid 21698 Glycoursodeoxycholic Acid 20290 Murideoxycholic Acid *Also available: isotopically labeled internal standards 2020 CAYMAN CHEMICAL · 1180 EAST ELLSWORTH ROAD · ANN ARBOR, MI 48108 · USA · (800) 364-9897 WWW.CAYMANCHEM.COM Bile Acids, Conjugates, and Metabolites (continued) Item No. -
Table S1. List of Liver, Fecal, Serum Bile Acid, and Internal Standards (IS) Names and Abbreviations
Table S1. List of liver, fecal, serum bile acid, and internal standards (IS) names and abbreviations. Abbreviation Bile Acid Name 12 KLCA 3α-Hydroxy-12 Ketolithocholic Acid 3, 7, 12 DHCA 3,7,12 Dehydrocholic acid 3,12-DKCA 3,12-Diketocholanic Acid 3,6-DKCA 3,6-Diketocholanic Acid 3,7-DKCA 3,7-Diketocholanic Acid 3-EpiDCA 5β-Cholanic Acid-3β, 12α-diol 5β-CA-3a,6a-diol-7-one 5β-Cholanic Acid-3α, 6α-diol-7-one 5β-CA-7a-ol-3-one 5β-Cholenic Acid-7α-ol-3-one 8(14), 5β-CA-3α, 12α-diol 8(14), 5β-Cholenic Acid-3α, 12α-diol 7 KLCA 3α-Hydroxy-7 Ketolithocholic Acid 7, 12 DKCA 3α-Hydroxy-7,12-Diketocholanic Acid 9(11)-CA 9(11), (5β)-Cholenic Acid-3α-ol-12-one ALCA Allolithocholic Acid AlloCA Allocholanic acid ApoCA Apocholic acid CA Cholic acid CDCA Chenodeoxycholic acid DCA Deoxycholic acid DHCA 3-Dehydrocholic Acid GDCA Glycodeoxycholic acid GLCA Glycolithocholic Acid HCA Hyocholic acid HDCA Hyodeoxycholic acid IsoDCA Isodeoxycholic Acid IsoLCA Isolithocholic Acid KCA 3-Ketocholanic Acid LC Lithocholic acid LCA Lithocholenic acid MuriDCA Murideoxycholic acid MuroCA Murocholic Acid norDCA 3α,12α, 23-Nordeoxycholic Acid TCA Taurocholic acid TCDCA Taurochenodeoxycholic acid TDCA Taurodeoxycholic acid THCA Taurohyocholic Acid THDCA Taurohyodeoxycholic Acid TLCA Taurolithocholic Acid TUCA Tauro-ursocholanic Acid TUDCA Tauroursodeoxycholic acid TαMCA Tauro-β-muricholic acid TβMCA Tauro-α-muricholic acid TωMCA Tauro-ω-muricholic acid UCA Ursocholanic Acid UDCA Ursodeoxycholic acid αMCA Alpha-Muricholic acid βMCA Beta- Muricholic acid ωMCA Omega- Muricholic acid LC-d4 (IS) Lithocholic Acid-d4 DCA-d4 (IS) Deoxycholic Acid-d4 CDCA-d4 (IS) Chenodeoxycholic Acid-d4 UDCA-d4 (IS) Ursodeoxycholic Acid-d4 HDCA-d4 (IS) Hyodeoxycholic Acid-d5 CA-d4 (IS) Cholic Acid-d4 GLCA-d4 (IS) Glycolithocholic Acid-d4 GCDCA-d4 (IS) Glycochenodeoxycholic Acid-d4 GDCA-d4 (IS) Glycodeoxycholic Acid-d4 GUDCA-d4 (IS) Glycoursodeoxycholic Acid-d4 GCA-d4 (IS) Glycocholic Acid-d4 TLCA-d4 (IS) Taurolithocholic Acid-d4 TUDCA-d4 (IS) Tauroursodeoxycholic Acid-d5 TCA-d4 (IS) Taurocholic Acid-d4 Figure S1. -
Comprehensive and Semi-Quantitative Analysis Of
www.nature.com/scientificreports OPEN Comprehensive and semi- quantitative analysis of carboxyl- containing metabolites related to gut microbiota on chronic kidney disease using 2-picolylamine isotopic labeling LC-MS/MS Yoshitomi Kanemitsu1, Eikan Mishima 2, Masamitsu Maekawa 1*, Yotaro Matsumoto3, Daisuke Saigusa1,4, Hiroaki Yamaguchi1, Jiro Ogura1, Hiroki Tsukamoto3, Yoshihisa Tomioka3, Takaaki Abe 2,5 & Nariyasu Mano1 Carboxyl-containing metabolites, such as bile acids and fatty acids, have many important functions and microbiota is involved in the production of them. In the previous study, we found that the chronic kidney disease (CKD) model mice raised under germ-free conditions provided more severe renal damage than the mice with commensal microbiota. However, the precise infuence by the microbiome and carboxyl-containing metabolites to the renal functions is unknown. In this study, we aimed to develop a novel chemical isotope labeling-LC-MS/MS method using the 2-picolylamine and its isotopologue and applied the analysis of efects of microbiome and CKD pathophysiology. The developed semi- quantitative method provided the high accuracy not inferior to the absolute quantifcation. By comparing of four groups of mice, we found that both microbiota and renal function can alter the composition and level of these metabolites in both plasma and intestine. In particular, the intestinal level of indole-3-acetic acid, short-chain fatty acids and n-3 type of polyunsaturated fatty acid, which play important roles in the endothelial barrier function, were signifcantly lower in germ-free conditions mice with renal failure. Accordingly, it is suggested these metabolites might have a renoprotective efect on CKD by suppressing epithelial barrier disruption. -
Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation S
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2018/11/08/dmd.118.083691.DC1 1521-009X/47/2/86–93$35.00 https://doi.org/10.1124/dmd.118.083691 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 47:86–93, February 2019 Copyright ª 2019 by The American Society for Pharmacology and Experimental Therapeutics Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation s Yuan Tian, Jingwei Cai, Wei Gui, Robert G. Nichols, Imhoi Koo, Jingtao Zhang, Mallappa Anitha, and Andrew D. Patterson Department of Veterinary and Biomedical Sciences, Pennsylvania State University, University Park, Pennsylvania (Y.T., J.C., W.G., R.G.N., I.K., J.Z., M.A., A.D.P.); and Chinese Academy of Sciences Key Laboratory of Magnetic Resonance in Biological Systems, State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, National Centre for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, University of Chinese Academy of Sciences, Wuhan, People’s Republic of China (Y.T.) Received July 31, 2018; accepted November 7, 2018 Downloaded from ABSTRACT Intestinal bacteria play an important role in bile acid metabolism and intestinal FXR, which can mediate bile acid, lipid, and glucose in the regulation of multiple host metabolic pathways (e.g., lipid and metabolism. In vitro, isolated mouse cecal bacteria were incubated glucose homeostasis) through modulation of intestinal farnesoid with three doses of BBR (0.1, 1, and 10 mg/ml) for 4 hours in an X receptor (FXR) activity. Here, we examined the effect of berber- anaerobic chamber. -
Hepatic Microsomal Bile Acid Biotransformation Studies Carried out So Far Seem to Be Restricted by Concentrating Only on CYP3A-Mediated Bile Acid Biotransformation
HEPATIC MICROSOMAL BILE ACID BIOTRANSFORMATION: IDENTIFICATION OF METABOLITES AND CYTOCHROME P450 ENZYMES INVOLVED by Anand K. Deo B. Pharm., University of Pune, India, 2000 M. Pharm. Sci., University of Mumbai, 2002 M.Sc., The University of British Columbia, 2005 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in THE FACULTY OF GRADUATE STUDIES (PHARMACEUTICAL SCIENCES) THE UNIVERSITY OF BRITISH COLUMBIA Vancouver February 2009 © ANAND K. DEO, 2009 ABSTRACT Bile acids are end-products of cholesterol metabolism and essential for absorption of dietary lipids in the body. Impaired bile flow leads to hepatic bile acid accumulation and liver damage. Hepatic microsomal oxidation offers a potential mechanism for efficient elimination of bile acids. The present study investigated the cytochrome P450 (P450)-mediated hepatic microsomal biotransformation profiles of lithocholic acid, cholic acid and chenodeoxycholic acid using a liquid chromatography-mass spectrometry (LCIMS) based assay. Incubation of lithocholic acid with rat hepatic microsomes resulted in the formation of a major 6J3-hydroxylated metabolite, murideoxycholic acid, followed by isolithocholic acid and 3- ketocholanoic acid. Ursodeoxycholic acid, hyodeoxycholic acid and 6-ketolithocholic acid were identified as minor metabolites. Studies using P450-specific antibodies, chemical inducers, and rat recombinant enzymes showed that formation of murideoxycholic acid and 3-ketocholanoic acid were mediated by CYP3A2 and CYP2C 11. Similar metabolite profiles were obtained by incubation of lithocholic acid with mouse hepatic microsomes generating murideoxycholic acid as the major metabolite. Studies using P450 inducers and chemical inhibitors suggested the involvement of murine CYP3A in murideoxycholic acid and 3-ketocholanoic acid formation, and CYP1A, CYP2B and CYP3A enzymes in ursodeoxycholic acid, hyodeoxycholic acid and 6-ketolithocholic acid formation by mouse liver microsomes.